PD-1/PD-L1 co-inhibition shapes anticancer T cell immunodominance: facing the consequences of an immunological ménage à trois.

Haeryfar, S M Mansour; Schell, Todd D

Haeryfar, S M Mansour; Schell, Todd D.

Affiliation

Haeryfar SMM; Department of Microbiology and Immunology, Western University, 1151 Richmond Street, London, ON, N6A 5C1, Canada. Mansour.Haeryfar@schulich.uwo.ca.
Schell TD; Division of Clinical Immunology and Allergy, Department of Medicine, Western University, London, ON, N6A 5A5, Canada. Mansour.Haeryfar@schulich.uwo.ca.

Cancer Immunol Immunother ; 67(11): 1669-1672, 2018 Nov.

Article in En | MEDLINE | ID: mdl-30132082

Subject(s)

Antibodies, Monoclonal/therapeutic use; B7-H1 Antigen/antagonists & inhibitors; Immunotherapy; Neoplasms/drug therapy; Programmed Cell Death 1 Receptor/antagonists & inhibitors; T-Lymphocytes/immunology; Animals; Antigen Presentation; B7-H1 Antigen/immunology; Humans; Neoplasms/immunology; Programmed Cell Death 1 Receptor/immunology

Key words

CD8+ T cells; Cancer; Checkpoint inhibitors; Immunodominance; PD-1; PD-L1

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: T-Lymphocytes / B7-H1 Antigen / Programmed Cell Death 1 Receptor / Immunotherapy / Antibodies, Monoclonal / Neoplasms Limits: Animals / Humans Language: En Journal: Cancer Immunol Immunother Journal subject: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Year: 2018 Type: Article Affiliation country: Canada

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google